Loading
A phase 3 trial in triple-negative breast cancer, run by Fudan University, now recruiting.
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer is a phase 3, randomised interventional study registered as NCT05806060 by Fudan University, with a registry enrolment figure of 134 participants, started 2023-04-25 and due to reach its primary completion in 2026-05-01. Interventions recorded: VEGFR and TPC; TPC. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) with BLIS subtype". Sites: China. No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.